NEW YORK – Abbott and Fujirebio announced on Monday that they are partnering to develop a research-use-only test for neurofilament-light chain (NfL).
The neurology biomarker assay will be available for use on Abbott's Alinity I instrument and will be offered to researchers conducting studies demonstrating the utility of the NfL biomarker, the companies said in a statement. The firms are aiming to make the test available by 2025, and it will be the first RUO assay for the Alinity I system, they added.
NfL is being explored as a biomarker for multiple neurological diseases, including multiple sclerosis, Alzheimer's disease, and traumatic brain injury, the companies noted.
"Bringing NfL to Alinity I will allow researchers to benefit from the ease and functionality of Abbott's Alinity I instruments, which are available in labs across the US," Beth McQuiston, medical director in Abbott's diagnostics business, said in a statement. "Biomarkers are playing a critical role in how we identify and treat diseases and having the appropriate testing technology will help support and advance neuroscience research."
The Alinity I is Abbott's immunoassay system and uses chemiluminescent detection technology.